Obecabtagene autoleucel is a type of CAR T-cell therapy designed to treat certain blood cancers. It works by using your own immune cells (T cells), which are collected and then genetically modified in the lab to express a chimeric antigen receptor (CAR) that specifically targets CD19, a protein found on the surface of B cells, including cancerous B cells in acute lymphoblastic leukemia (ALL).

Once infused back into your body, these modified T cells seek out and bind to CD19-expressing cells. This binding activates the T cells, leading to the destruction of the cancerous B cells. The therapy also includes co-stimulatory domains (4-1BB and CD3-zeta) that help the T cells multiply and persist in your body, enhancing their ability to fight the cancer over time. After treatment, a period of low B cell counts (B cell aplasia) is expected as a sign of the therapy working.

Obecabtagene autoleucel

Common brand names

Approved use in